Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 23, 2010 - Issue 4
Submit an article Journal homepage
60
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Clostridium Difficile–Associated Diarrhea in a Tertiary Care Medical Center

Marilee D. Obritsch
, PharmD, BCPS,
Jeffrey S. StroupCorrespondence[email protected]
, PharmD, BCPS,
Ryan M. Carnahan
, PharmD, MS, BCPP &
David N. Scheck
, MD
Pages 363-367 | Published online: 11 Dec 2017

  • Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16 (8): 459–477.
  • Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM 2nd, Killgore G, Tenover FC. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38 (5): 640–645.
  • Groschel DHM. Clostridium difficile infection. Crit Rev Clin Lab Sci 1996;33 (3): 203–245.
  • McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990;162 (3): 678–684.
  • Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008;46 (Suppl 1): S19–S31.
  • Gerding DN, Olson MM, Peterson LR, Teasley DG, Gebhard RL, Schwartz ML, Lee JT Jr. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986;146 (1): 95–100.
  • Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974;81 (4): 429–433.
  • Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120 (4): 272–277.
  • Bartlett JG. Antibiotic-associated colitis. Dis Mon 1984;30 (15): 1–54.
  • Golledge CL, Carson CF, O'Neill GL, Bowman RA, Riley TV. Ciprofloxacin and Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 1992;30 (2): 141–147.
  • Yip C, Loeb M, Salama S, Moss L, Olde J. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001;22 (9): 572–575.
  • Bauwens JE, McFarland LV, Melcher SA. Recurrent Clostridium difficile disease following ciprofloxacin use. Ann Pharmacother 1997;31 (9): 1090.
  • McFarland LV, Bauwens JE, Melcher SA, Surawicz CM, Greenberg RN, Elmer GW. Ciprofloxacin-associated Clostridium difficile disease. Lancet 1995;346 (8980): 977–978.
  • Cain DB, O'Connor ME. Pseudomembranous colitis associated with ciprofloxacin. Lancet 1990;336 (8720): 946.
  • Dan M, Samra Z. Clostridium difficile colitis associated with ofloxacin therapy. Am J Med 1989;87 (4): 479.
  • Ozawa TT, Valadez T. Clostridium difficile infection associated with levofloxacin treatment. Tenn Med 2002;95 (3): 113–115.
  • Ortiz-de-Saracho J, Pantoja L, Romero MJ, López R. Moxifloxacin-induced Clostridium difficile diarrhea. Ann Pharmacother 2003;37 (3): 452–453.
  • Carroll DN. Moxifloxacin-induced Clostridium difficile-associated diarrhea. Pharmacotherapy 2003;23 (11): 1517–1519.
  • Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26 (3): 273–280.
  • McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9 (6): 730–733.
  • Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171 (1): 33–38.
  • Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54 (3): 243–245.
  • SAS Institute Inc. SAS/STAT Users Guide, Version 9.1. Cary, NC: SAS Institute Inc., 2002–2003.
  • Adams DA, Riggs MM, Donskey CJ. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob Agents Chemother 2007;51 (8): 2674–2678.
  • Gallagher JC, Du JK, Rose C. Severe pseudomembranous colitis after moxifloxacin use: a case series. Ann Pharmacother 2009;43 (1): 123–128.
  • Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rochon PA, Juurlink DN. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother 2006;50 (9): 3216–3219.
  • Biller P, Shank B, Lind L, Brennan M, Tkatch L, Killgore G, Thompson A, McDonald LC. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007;28 (2): 198–201.
  • McFarland LV, Clarridge JE, Beneda HW, Raugi GJ. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. Clin Infect Dis 2007;45 (9): 1141–1151.
  • Walbrown MA, Aspinall SL, Bayliss NK, Stone RA, Cunningham F, Squier CL, Good CB. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones. J Manag Care Pharm 2008;14 (1): 34–40.
  • Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353 (23): 2442–2449.
  • Kazakova SV, Ware K, Baughman B, Bilukha O, Paradis A, Sears S, Thompson A, Jensen B, Wiggs L, Bessette J, Martin J, Clukey J, Gensheimer K, Killgore G, McDonald LC. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006;166 (22): 2518–2524.
  • Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41 (9): 1254–1260.
  • Deshpande A, Pant C, Jain A, Fraser TG, Rolston DD. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin 2008;24 (2): 329–333.
  • Cunningham R, Dial S. Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea? J Hosp Infect 2008;70 (1): 1–6.
  • Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006;43 (10): 1272–1276.
  • Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294 (23): 2989–2995.
  • Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008;103 (9): 2308–2313.
  • Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment Pharmacol Ther 2009;29 (6): 626–634.
  • Pierce PF Jr, Wilson R, Silva J Jr, Garagusi VF, Rifkin GD, Fekety R, Nunez-Montiel O, Dowell VR Jr, Hughes JM. Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. J Infect Dis 1982;145 (2): 269–274.
  • Winston DJ, Lazarus HM, Beveridge RA, Hathorn JW, Gucalp R, Ramphal R, Chow AW, Ho WG, Horn R, Feld R, Louie TJ, Territo MC, Blumer JL, Tack KJ. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 2001;32 (3): 381–390.
  • Bodey G, Abi-Said D, Rolston K, Raad I, Whimbey E. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996;15 (8): 625–634.
  • Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, Rubin M, Jarosinski P, Gill V, Young RC, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13 (1): 165–176.
  • Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29 (1): 44–50.
  • Tanner J, Khan D, Anthony D, Paton J. Waterlow score to predict patients at risk of developing Clostridium difficile-associated disease. J Hosp Infect 2009;71 (3): 239–244.
  • Garey KW, Dao-Tran TK, Jiang ZD, Price MP, Gentry LO, Dupont HL. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect 2008;70 (2): 142–147.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.